Javed Butler, MD: Clinical Benefits of Patiromer in Reducing Hyperkalemia - MD Magazine

The majority of patients with HFrEF and RAASi-related hyperkalemia achieved optimal doses of RAASi when treated with patiromer.

New findings suggest patients taking renin-angiotensin-aldosterone system inhibitor (RAASi) medication for heart failure with reduced ejection fraction (HFrEF) had much lower blood potassium levels w… [+2188 chars]

full article...